AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18375779 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotores-led diabetes self-management education and follow-up
Number of subjects: 131
Study 18375779 — intervention group
Group type: COMPARATOR
Intervention: Usual diabetic care (wait-list control group)
Number of subjects: 131
Study 16002810 — intervention group
Group type: EXPERIMENTAL
Intervention: High-DHA algal oil (approximately 200 mg DHA/d)
Number of subjects: 0
Study 16002810 — intervention group
Group type: COMPARATOR
Intervention: Vegetable oil (no DHA)
Number of subjects: 0
Study 12435860 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO (3.3 X 10(4) IU/50 ml/30 min) once daily for the first 3 days after stroke
Number of subjects: 53
Study 12435860 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO administered within 5 hours of symptom onset
Number of subjects: 53
Study 12435860 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 53
Study 9793962 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent histological sections obtained from prostate carcinoma material processed from fine needle aspirates.
Number of subjects: 0
Study 9793962 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunocytochemistry (ICC) procedures applied to tumor sections.
Number of subjects: 0
Study 7894455 — intervention group
Group type: EXPERIMENTAL
Intervention: ChEAT scores
Number of subjects: 476
Study 7894455 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire to lose weight
Number of subjects: 476
Study 7894455 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-losing behaviors
Number of subjects: 476
Study 7894455 — intervention group
Group type: EXPERIMENTAL
Intervention: At-risk index by gender
Number of subjects: 476
Study 7894455 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoccupation with thinness and weight-losing behaviors
Number of subjects: 476
Study 7894455 — intervention group
Group type: EXPERIMENTAL
Intervention: DDQ items
Number of subjects: 476
Study 2673316 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 60 mg twice daily for 4 weeks
Number of subjects: 11
Study 2673316 — intervention group
Group type: COMPARATOR
Intervention: Nicardipine
Number of subjects: 11
Study 327942 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone aerosol given intranasally for 3 weeks (active drug)
Number of subjects: 44
Study 327942 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 weeks (control)
Number of subjects: 44
Study 30916450 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-strategic memory training (MMT) - 10 weekly 90-min sessions
Number of subjects: 201
Study 30916450 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-strategic memory training (MMT)
Number of subjects: 201
Study 30916450 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 201
Study 27789170 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents
Number of subjects: 804
Study 27789170 — intervention group
Group type: EXPERIMENTAL
Intervention: Postintervention minimum lumen area (MLA) at the target lesion
Number of subjects: 804
Study 27789170 — intervention group
Group type: EXPERIMENTAL
Intervention: MLA/distal reference segment lumen area ratio
Number of subjects: 804
Study 27789170 — intervention group
Group type: EXPERIMENTAL
Intervention: MLA < 5.0 mm2
Number of subjects: 804
Study 26105531 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural blood patch (EBP) treatment following accidental dural puncture (ADP)
Number of subjects: 60
Study 22496352 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) - either nicotine patch or nicotine gum for 5 weeks
Number of subjects: 6261
Study 22496352 — intervention group
Group type: COMPARATOR
Intervention: No intervention cohort
Number of subjects: 6261
Study 21752257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (20 sessions over 30 weeks)
Number of subjects: 540
Study 21752257 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Term Psychoanalytic Therapy (30 sessions over 30 weeks)
Number of subjects: 540
Study 21752257 — intervention group
Group type: COMPARATOR
Intervention: Specialist Clinical Care (12 sessions over 20 weeks)
Number of subjects: 540
Study 19174696 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg daily with compliance-enhancing program
Number of subjects: 8108
Study 19174696 — intervention group
Group type: COMPARATOR
Intervention: rosuvastatin 10 mg daily without compliance-enhancing program
Number of subjects: 8108
Study 19174696 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg daily with compliance-enhancing program in statin-naive patients
Number of subjects: 8108
Study 19174696 — intervention group
Group type: COMPARATOR
Intervention: rosuvastatin 10 mg daily without compliance-enhancing program in statin-naive patients
Number of subjects: 8108
Study 17096684 — intervention group
Group type: COMPARATOR
Intervention: Mizoribine 12 mg kg(‐1) day(‐1) (multiple-dose study)
Number of subjects: 48
Study 17096684 — intervention group
Group type: COMPARATOR
Intervention: Mizoribine 3, 6, 9, and 12 mg kg(‐1) (single-dose study)
Number of subjects: 48
Study 17096684 — intervention group
Group type: COMPARATOR
Intervention: Mizoribine 6 mg kg(‐1) day(‐1) once daily for 5 days (multiple-dose study)
Number of subjects: 48
Study 17096684 — intervention group
Group type: COMPARATOR
Intervention: Mizoribine 12 mg kg(‐1) day(‐1) twice daily for 7 days (multiple-dose study)
Number of subjects: 48
Study 15050853 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby‐Friendly hospital Initiative training programs
Number of subjects: 4614
Study 15050853 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4614
Study 11696472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary NO synthase inhibition with N(G)‐monomethyl‐L‐arginine (L‐NMMA; 25 micromol/min)
Number of subjects: 18
Study 9400037 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 169
Study 9400037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 7781205 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (160 mumol/min i.v. for 3 hours)
Number of subjects: 18
Study 2223361 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural administration of methadone 5 mg
Number of subjects: 42
Study 2223361 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 42
Study 666305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil (15 mg/kg)
Number of subjects: 50
Study 666305 — intervention group
Group type: COMPARATOR
Intervention: Penicillin G
Number of subjects: 50
Study 29614887 — intervention group
Group type: EXPERIMENTAL
Intervention: SOVT posture during Vocal Function Exercises (VFEs)
Number of subjects: 26
Study 29614887 — intervention group
Group type: COMPARATOR
Intervention: Vowel /o/ during Vocal Function Exercises (VFEs)
Number of subjects: 26
Study 29614887 — intervention group
Group type: COMPARATOR
Intervention: Vowel /a/ during Vocal Function Exercises (VFEs)
Number of subjects: 26
Study 27909781 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-magnitude mechanical stimulation (LMMS)
Number of subjects: 41
Study 27909781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 24661390 — intervention group
Group type: EXPERIMENTAL
Intervention: iVAPS
Number of subjects: 18
Study 24661390 — intervention group
Group type: COMPARATOR
Intervention: standard PS
Number of subjects: 18
Study 22659702 — intervention group
Group type: EXPERIMENTAL
Intervention: IOTN training
Number of subjects: 30
Study 22659702 — intervention group
Group type: EXPERIMENTAL
Intervention: ICON training
Number of subjects: 30
Study 22659702 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 30
Study 21197490 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-bar (splinted mini-implants with a prefabricated bar)
Number of subjects: 45
Study 21197490 — intervention group
Group type: COMPARATOR
Intervention: Group-ball (two single ball-type mini-implants)
Number of subjects: 45
Study 21197490 — intervention group
Group type: COMPARATOR
Intervention: Group-ball
Number of subjects: 45
Study 21197490 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-bar
Number of subjects: 45
Study 18544286 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery stress reduction program
Number of subjects: 34
Study 15668556 — intervention group
Group type: EXPERIMENTAL
Intervention: Local corticosteroid injection (40 mg of methylprednisolone acetate)
Number of subjects: 30
Study 15668556 — intervention group
Group type: COMPARATOR
Intervention: Iontophoresis of dexamethasone sodium phosphate
Number of subjects: 30
Study 14506619 — intervention group
Group type: EXPERIMENTAL
Intervention: MgC-Cre (Magnesium-creatine chelate) at 800 mg Mg and 5 g Cre per day for 2 weeks
Number of subjects: 35
Study 14506619 — intervention group
Group type: EXPERIMENTAL
Intervention: MgO-Cre (Magnesium oxide plus creatine) at 800 mg Mg and 5 g Cre per day for 2 weeks
Number of subjects: 35
Study 14506619 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (Placebo)
Number of subjects: 35
Study 10382900 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin (two 250 mg tablets od)
Number of subjects: 12
Study 10382900 — intervention group
Group type: COMPARATOR
Intervention: Theophylline alone (control phase)
Number of subjects: 12
Study 8525439 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 25
Study 8525439 — intervention group
Group type: COMPARATOR
Intervention: Open (laparotomic) cholecystectomy
Number of subjects: 25
Study 2407808 — intervention group
Group type: EXPERIMENTAL
Intervention: IRS-I (1972 to 1978)
Number of subjects: 1688
Study 2407808 — intervention group
Group type: EXPERIMENTAL
Intervention: IRS-II (1978 to 1984)
Number of subjects: 1688
Study 2407808 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III tumors
Number of subjects: 1688
Study 2407808 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical group I (localized disease, completely resected)
Number of subjects: 1688
Study 2407808 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical group II
Number of subjects: 1688
Study 2407808 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical group III
Number of subjects: 1688
Study 2407808 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical group IV (metastatic disease)
Number of subjects: 1688
Study 2407808 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-free survival
Number of subjects: 1688
Study 6985742 — intervention group
Group type: EXPERIMENTAL
Intervention: iopronic acid (4.5 g)
Number of subjects: 260
Study 6985742 — intervention group
Group type: COMPARATOR
Intervention: iopanoic acid (3.0 g)
Number of subjects: 260
Study 6985742 — intervention group
Group type: EXPERIMENTAL
Intervention: iopronic acid
Number of subjects: 260
Study 6985742 — intervention group
Group type: COMPARATOR
Intervention: iopanoic acid
Number of subjects: 260
Study 31874525 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant HIPEC
Number of subjects: 91
Study 31874525 — intervention group
Group type: COMPARATOR
Intervention: Standard systemic chemotherapy
Number of subjects: 91
Study 28291050 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exposure prophylaxis (PrEP)
Number of subjects: 0
Study 25596472 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1mg/kg)
Number of subjects: 4494
Study 25596472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4494
Study 23959510 — intervention group
Group type: EXPERIMENTAL
Intervention: Array SA40N (AMO, Irvine, CA, USA)
Number of subjects: 229
Study 23959510 — intervention group
Group type: EXPERIMENTAL
Intervention: SA60D3 ReSTOR (Alcon, Fort Worth, TX, USA)
Number of subjects: 229
Study 23959510 — intervention group
Group type: COMPARATOR
Intervention: MA60AC (Alcon, Fort Worth, TX, USA)
Number of subjects: 229
Study 21349488 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels
Number of subjects: 200
Study 21349488 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels with low MVPA (16 hours/week)
Number of subjects: 200
Study 21349488 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels with moderate MVPA (35 hours/week)
Number of subjects: 200
Study 21349488 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels with high MVPA (64 hours/week)
Number of subjects: 200
Study 18835437 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid vaccine with psychological stress
Number of subjects: 59
Study 18835437 — intervention group
Group type: COMPARATOR
Intervention: Typhoid vaccine with rest
Number of subjects: 59
Study 18835437 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline placebo with psychological stress
Number of subjects: 59
Study 18835437 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo with rest
Number of subjects: 59
Study 17920287 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 22
Study 17920287 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH
Number of subjects: 22
Study 17920287 — intervention group
Group type: COMPARATOR
Intervention: Switch from enoxaparin to UFH
Number of subjects: 22
Study 15534166 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 2231
Study 15534166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2231
Study 15534166 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 2231
Study 11181804 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis with dextrose alone
Number of subjects: 18
Study 11181804 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis with dextrose and amino acids
Number of subjects: 18
Study 11181804 — intervention group
Group type: COMPARATOR
Intervention: Time controls (baseline state)
Number of subjects: 18
Study 9562302 — intervention group
Group type: EXPERIMENTAL
Intervention: Granule cell dispersion (GCD) observed in hippocampal specimens
Number of subjects: 22
Study 9562302 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of GCD
Number of subjects: 22
Study 7719221 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cancer patients with second cancers
Number of subjects: 1090
Study 7719221 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with second cancers
Number of subjects: 1090
Study 7719221 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial localized cancer
Number of subjects: 1090
Study 2906897 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg bopindolol
Number of subjects: 115
Study 2906897 — intervention group
Group type: COMPARATOR
Intervention: 0 mg (placebo)
Number of subjects: 115
Study 2906897 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg bopindolol
Number of subjects: 115
Study 29338142 — intervention group
Group type: EXPERIMENTAL
Intervention: Background infusion of 5 mL/h plus 5 mL demand bolus doses with 10-minute lockout (group B/D)
Number of subjects: 52
Study 29338142 — intervention group
Group type: COMPARATOR
Intervention: Only demand bolus doses of 5 mL with 10-minute lockout (group D)
Number of subjects: 52
Study 27235956 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute music
Number of subjects: 133
Study 27235956 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute music
Number of subjects: 133
Study 27235956 — intervention group
Group type: COMPARATOR
Intervention: Control (no music)
Number of subjects: 133
Study 24010876 — intervention group
Group type: EXPERIMENTAL
Intervention: CS21 barrier genital gel®
Number of subjects: 61
Study 24010876 — intervention group
Group type: COMPARATOR
Intervention: Topical aciclovir
Number of subjects: 61
Study 24010876 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 61
Study 23563040 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (3 g daily)
Number of subjects: 41
Study 23563040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 20568429 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp penetration acupuncture through Baihui (GV 20) to Taiyang (EX‐HN 5) on the affected side, with four needles relay.
Number of subjects: 60
Study 20568429 — intervention group
Group type: COMPARATOR
Intervention: Conventional scalp acupuncture at anterior oblique line of parietotemporal region, with four needles relay.
Number of subjects: 60
Study 18266835 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (specific intervention details not available)
Number of subjects: 0
Study 18266835 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog ownership (year 1)
Number of subjects: 0
Study 18266835 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory syncytial viral infection (detected at 12 months)
Number of subjects: 0
Study 18266835 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal smoking (year 7)
Number of subjects: 0
Study 18266835 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog ownership (year 2)
Number of subjects: 0
Study 18266835 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor environmental exposures (year 7)
Number of subjects: 0
Study 16390901 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic/affective symptoms
Number of subjects: 2466
Study 16390901 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive/affective symptoms
Number of subjects: 2466
Study 16390901 — intervention group
Group type: EXPERIMENTAL
Intervention: Appetitive symptoms
Number of subjects: 2466
Study 12595785 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT plus imipramine
Number of subjects: 0
Study 12595785 — intervention group
Group type: COMPARATOR
Intervention: CBT plus placebo
Number of subjects: 0
Study 10916893 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG): Group health education session and postal back-up every three months for two years
Number of subjects: 110
Study 10916893 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG): Health education from their doctor
Number of subjects: 110
Study 8752182 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS(+) pattern (n = 85)
Number of subjects: 378
Study 8752182 — intervention group
Group type: COMPARATOR
Intervention: QRS(−) pattern (n = 293)
Number of subjects: 378
Study 8752182 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior AMI with QRS(+)
Number of subjects: 378
Study 8752182 — intervention group
Group type: COMPARATOR
Intervention: Non-anterior AMI
Number of subjects: 378
Study 1569622 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) 30/ng/kg/min IV for up to 7 days
Number of subjects: 146
Study 1569622 — intervention group
Group type: COMPARATOR
Intervention: Placebo IV for up to 7 days
Number of subjects: 146
Study 2868899 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 31-1118 (10 mg)
Number of subjects: 5
Study 2868899 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 31-1118 (20 mg)
Number of subjects: 5
Study 2868899 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 31-1118 (40 mg)
Number of subjects: 5
Study 2868899 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 31-1118 (80 mg)
Number of subjects: 5
Study 2868899 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 31-1118 (all doses)
Number of subjects: 5
Study 2868899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31378648 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent storybook (celeriac)
Number of subjects: 337
Study 31378648 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent sensory play (celeriac)
Number of subjects: 337
Study 31378648 — intervention group
Group type: COMPARATOR
Intervention: Incongruent sensory play (carrot)
Number of subjects: 337
Study 31378648 — intervention group
Group type: COMPARATOR
Intervention: Storybook only conditions
Number of subjects: 337
Study 29514697 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy (GDFT)
Number of subjects: 0
Study 29514697 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 29514697 — intervention group
Group type: EXPERIMENTAL
Intervention: GDFT
Number of subjects: 0
Study 26901343 — intervention group
Group type: EXPERIMENTAL
Intervention: THC:CBD oromucosal spray
Number of subjects: 300
Study 24331983 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg acetaminophen/10 mg hydrocodone
Number of subjects: 100
Study 24331983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 21616626 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based Diabetes Interactive Education Programme (DIEP)
Number of subjects: 99
Study 20642326 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5-g progesterone vaginal rings (PVR)
Number of subjects: 44
Study 20642326 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-g progesterone vaginal rings (PVR)
Number of subjects: 44
Study 20642326 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol (50 microg/day)
Number of subjects: 44
Study 17569202 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) screening for lung cancer
Number of subjects: 0
Study 14998844 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin 840 mg/m2 administered continuously during 6 weeks of radiotherapy (60 Gy)
Number of subjects: 160
Study 14998844 — intervention group
Group type: COMPARATOR
Intervention: Thoracic radiotherapy alone (60 Gy)
Number of subjects: 160
Study 12421891 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal application of lysine aspirin for two weeks (5 patients)
Number of subjects: 34
Study 12421891 — intervention group
Group type: COMPARATOR
Intervention: Placebo for two weeks (4 patients)
Number of subjects: 34
Study 12421891 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal application of lysine aspirin for six months (5 patients)
Number of subjects: 34
Study 12421891 — intervention group
Group type: COMPARATOR
Intervention: Placebo for six months (4 patients)
Number of subjects: 34
Study 9843456 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 586
Study 9843456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586
Study 7863253 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg/day for one year (Group A)
Number of subjects: 581
Study 7863253 — intervention group
Group type: COMPARATOR
Intervention: Intermittent treatment with nizatidine (Group B)
Number of subjects: 581